EVALUATION OF CRESS IN THE PHASE 2 RANDOMISED PLACEBO-CONTROLLED STUDY OF SEQUENTIAL BELIMUMAB/RITUXIMAB ADMINISTRATION IN PATIENTS WITH PRIMARY SJOGREN'S SYNDROME

被引：2

作者：

Bootsma, H. ^{[1
]}

Arends, S. ^{[1
]}

de Wolff, L. ^{[1
]}

Clark, K. L. ^{[2
]}

van Maurik, A. ^{[3
]}

Mistry, P. ^{[4
]}

Shukla, P. ^{[5
]}

Nihtyanova, S. ^{[6
]}

Fox, N. L. ^{[7
]}

Roth, D. ^{[8
]}

机构：

[1] Univ Groningen, Univ Med Ctr Groningen, Dept Rheumatol & Clin Immunol, Groningen, Netherlands

[2] GlaxoSmithKline, Clin Sci, Stevenage, Herts, England

[3] GlaxoSmithKline, Clin Pharmacol & Expt Med, Stevenage, Herts, England

[4] GlaxoSmithKline, R&D Biostat, Stevenage, Herts, England

[5] GlaxoSmithKline, R&D Biostat, Bangalore, India

[6] GlaxoSmithKline, Clin Sci, London, England

[7] GlaxoSmithKline, Clin Dev, Collegeville, PA USA

[8] GlaxoSmithKline, R&D, Collegeville, PA USA

来源：

关键词：

D O I：

10.1136/annrheumdis-2022-eular.1336

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

POS0193

引用

页码：329 / 330

页数：2

共 2 条